Evaluation Of Diagnostic Methods In Patients With Prostatic Adenocarcinoma

Objective: To evaluate diagnostic methods in patients with prostatic adenocarcinoma and relationships between serum levels of PSA and clinical stages, pathological grades. Methods: Both 36 patients with prostatic adenocacinoma and 81 patients with BPH were determined by pathological examination. Age, PSA levels and PSAD levels in patients with prostatic adenocacinoma were compared with which in patients with BPH. The relationships between PSA levels and clinical stages, pathological grades in patients with prostatic adenocarcinoma were evaluated. Results: There was no difference between age in patients with prostatic adenocarcinoma and age in patients with BPH.PSA and PSAD levels were difference between patients with prostatic adenocarcinoma and patients with BPH.When PSA level was of 4ng/ml or greater, the sensitivity of PSA as a method to detect prostatic adenocarcinoma was 89.29%, the specificity was 59.26% and the positive predictive value was 43.10%. When PSAD level was of 0.15 or greater, the sensitivity of PSAD as a method to detect prostatic adenocarcinoma was 81.82%, the specificity was 80.85% and the positive predictive value was 66.67%. PSA level was no difference between A to B stage and C to D stage.PSA level was no difference between Gleason scores less then 7 and Gleason scores 7 or greater. Conclusions: Age in patients with Prostatic adenocarcinoma and patients with BPH was similarly. Both PSA and PSAD had good values to detect prostatic adenocarcinoma and PSAD might be better. PSA as a predictor of prognosis could not be confirmed.